|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We investigated the expression of Sox11 in 132 diffuse astrocytomas in relation to the regulator cell marker nestin, c-Met and IDH1-R132H, which have shown to be differentially expressed among the molecular subgroups of malignant gliomas, as well as to an inducer of astrocytic differentiation, that is, signal transducer and activator of transcription (p-STAT-3), clinicopathological features and survival.
|
23619925 |
2013 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Of these, we recommend, OA,NOS and IDH1(R132H)-non-mt ODG,NOS to be our priority for performing 1p/19q co-deletion studies in comparison to IDH-mt ODG,NOS, and it would not be mandatory for astrocytoma.
|
28801347 |
2018 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here, an in-depth characterization of IDH1 R132H mutations were assessed by immunohistochemistry in 55 paired primary-recurrent astrocytomas tissues, including 5 paired primary pilocytic astrocytoma (pPA, WHO grade I), 35 paired primary low grade astrocytoma (pLGA, WHO grade II and III) and 15 paired primary high grade astrocytoma (pHGA/ Glioblastoma, WHO grade IV).
|
28928859 |
2017 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the subgroup of 142 glioma patients characterized by IDH1-R132H status, METT/N ratio demonstrated a significant prognostic impact in IDH1-R132H wildtype astrocytomas and glioblastoma (P = 0.001).
|
29016947 |
2018 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
IDH1 R132H mutations occur in approximately 70% of astrocytomas and oligodendroglial tumors.
|
19798509 |
2009 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
To study the putative expression patterns and clinical significance of Hsp27, we assessed the associations between Hsp27, R132H mutation of Isocitrate dehydrogenase1 (IDH1-R132H), Hypoxia-inducible factor subunit alpha (HIF-1 alpha), Carbonic anhydrase IX (CA IX), and patient prognosis in astrocytic gliomas.
|
24599602 |
2014 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Fractional anisotropy and ADC from DTI can noninvasively detect IDH1 R132H mutation in astrogliomas.
|
24557705 |
2014 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
As the presence of the p.R132H mutation in the IDH1 gene seems to be a more powerful prognostic marker than O(6)-methylguanine-DNA methyltransferase promoter status, we evaluated the presence of IDH1 mutation in Polish patients with astrocytoma, glioblastoma, oligoastrocytoma, ganglioglioma, oligodendroglioma, and ependymoma.
|
23934769 |
2014 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
No IDH1-R132H mutation was detected in 2 of 2 (0%) astrocytomas by immunohistochemistry.
|
26990854 |
2016 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Because many ALT tumors express the mutant isocitrate dehydrogenase IDH1 R132H, including all lower grade astrocytomas and secondary glioblastoma, we examined a hypothesized role for IDH1 R132H in driving the ALT phenotype during gliomagenesis.
|
29545335 |
2018 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Furthermore, IMab-1 specifically stained the IDH1(R132H)-expressing cells in astrocytomas in immunohistochemistry, whereas it did not react with IDH1(R132H)-negative primary glioblastoma sections.
|
19818334 |
2009 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
|
rs1057519903
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Additionally, H3F3A K27M was not detected in the 2 diffuse astrocytomas.
|
24285547 |
2014 |
|
rs1057519903
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Because H3F3A K27M mutations occur exclusively in pediatric diffuse high-grade astrocytomas, analysis of codon 27 mutational status could be useful in the differential diagnosis of these neoplasms.
|
23429371 |
2013 |
|
rs121913499
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Without exception, all were R132C (CGT-->TGT), which in sporadic astrocytomas accounts for <5% of IDH1 mutations.
|
19340432 |
2009 |
|
rs121913499
|
|
|
0.720 |
GeneticVariation |
BEFREE |
IDH1 mutations of the R132C type are strongly associated with astrocytoma, while IDH2 mutations predominantly occur in oligodendroglial tumors.
|
19554337 |
2009 |
|
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation seems to define a subset of malignant astrocytomas in children, in which there is frequent concomitant homozygous deletion of CDKN2A (five of seven cases).
|
20068183 |
2010 |
|
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
BRAF V600E mutation was observed both in epithelioid tumor cells and in diffusely infiltrating less atypical astrocytoma cells.
|
24354918 |
2014 |
|
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Thus BRAF V600E mutation is common in desmoplastic non-infantile astrocytoma/ganglioglioma, but does not affect the prognosis.
|
29902580 |
2018 |
|
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The BRAF(V600E) inhibitor PLX4720 significantly increased survival of mice after intracranial transplant of genetically relevant murine or human astrocytoma cells.
|
22586120 |
2012 |
|
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing.
|
25346165 |
2015 |
|
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Similar to previously reported findings on E-GBM associated with low-grade glioma, this case suggested that low-grade astrocytic glioma with BRAF V600E mutation progressed to E-GBM.
|
26602910 |
2016 |
|
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
With regard to implications for therapy, our results support evaluation of BRAF(V600E)-specific inhibitors for treating BRAF(V600E) MA patients.
|
22038996 |
2011 |
|
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma.
|
30972500 |
2019 |
|
rs121913377
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma.
|
30972500 |
2019 |